209 related articles for article (PubMed ID: 10799756)
1. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.
Wu HQ; Guidetti P; Goodman JH; Varasi M; Ceresoli-Borroni G; Speciale C; Scharfman HE; Schwarcz R
Neuroscience; 2000; 97(2):243-51. PubMed ID: 10799756
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
Carpenedo R; Meli E; Peruginelli F; Pellegrini-Giampietro DE; Moroni F
J Neurochem; 2002 Sep; 82(6):1465-71. PubMed ID: 12354294
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities.
Carpenedo R; Chiarugi A; Russi P; Lombardi G; Carlà V; Pellicciari R; Mattoli L; Moroni F
Neuroscience; 1994 Jul; 61(2):237-43. PubMed ID: 7969905
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
Ceresoli-Borroni G; Guidetti P; Schwarcz R
J Neural Transm (Vienna); 1999; 106(3-4):229-42. PubMed ID: 10392532
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Naritsin DB; Saito K; Markey SP; Chen CY; Heyes MP
J Neurochem; 1995 Nov; 65(5):2217-26. PubMed ID: 7595510
[TBL] [Abstract][Full Text] [Related]
6. 28833, a selective kynurenine 3-hydroxylase inhibitor. Effects on the kynurenine pathway metabolites in the gerbil.
Cini M; Bormetti R; Marconi M; Molinari A; Veneroni O; Varasi M; Schwarcz R; Speciale C
Adv Exp Med Biol; 1996; 398():535-8. PubMed ID: 8906318
[No Abstract] [Full Text] [Related]
7. Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents.
Speciale C; Cini M; Wu HQ; Salvati P; Schwarcz R; Molinari A; Calabresi M; Varasi M
Adv Exp Med Biol; 1996; 398():221-7. PubMed ID: 8906269
[No Abstract] [Full Text] [Related]
8. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P; Wu HQ; Schwarcz R
Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons.
Erhardt S; Oberg H; Mathé JM; Engberg G
Amino Acids; 2001; 20(4):353-62. PubMed ID: 11452979
[TBL] [Abstract][Full Text] [Related]
10. 2-Oxoacids regulate kynurenic acid production in the rat brain: studies in vitro and in vivo.
Hodgkins PS; Wu HQ; Zielke HR; Schwarcz R
J Neurochem; 1999 Feb; 72(2):643-51. PubMed ID: 9930736
[TBL] [Abstract][Full Text] [Related]
11. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
12. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase.
Chiarugi A; Carpenedo R; Moroni F
J Neurochem; 1996 Aug; 67(2):692-8. PubMed ID: 8764597
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase.
Chiarugi A; Carpenedo R; Molina MT; Mattoli L; Pellicciari R; Moroni F
J Neurochem; 1995 Sep; 65(3):1176-83. PubMed ID: 7643095
[TBL] [Abstract][Full Text] [Related]
14. In vivo assessment of kynurenate neuroprotective potency and quinolinate excitotoxicity.
Obrenovitch TP; Urenjak J
Amino Acids; 2000; 19(1):299-309. PubMed ID: 11026501
[TBL] [Abstract][Full Text] [Related]
15. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
[TBL] [Abstract][Full Text] [Related]
16. Increased cortical kynurenate content in schizophrenia.
Schwarcz R; Rassoulpour A; Wu HQ; Medoff D; Tamminga CA; Roberts RC
Biol Psychiatry; 2001 Oct; 50(7):521-30. PubMed ID: 11600105
[TBL] [Abstract][Full Text] [Related]
17. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
Guidetti P; Schwarcz R
Adv Exp Med Biol; 2003; 527():137-45. PubMed ID: 15206726
[TBL] [Abstract][Full Text] [Related]
19. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.
Pellicciari R; Natalini B; Costantino G; Mahmoud MR; Mattoli L; Sadeghpour BM; Moroni F; Chiarugi A; Carpenedo R
J Med Chem; 1994 Mar; 37(5):647-55. PubMed ID: 8126705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
